CN107375906B - 一种疤痕修复剂及其制备方法 - Google Patents
一种疤痕修复剂及其制备方法 Download PDFInfo
- Publication number
- CN107375906B CN107375906B CN201710631595.4A CN201710631595A CN107375906B CN 107375906 B CN107375906 B CN 107375906B CN 201710631595 A CN201710631595 A CN 201710631595A CN 107375906 B CN107375906 B CN 107375906B
- Authority
- CN
- China
- Prior art keywords
- parts
- scar
- solution
- repair agent
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 231100000241 scar Toxicity 0.000 title claims abstract description 101
- 230000008439 repair process Effects 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 46
- 239000002502 liposome Substances 0.000 claims abstract description 35
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 20
- 241000237858 Gastropoda Species 0.000 claims abstract description 13
- OLGWXCQXRSSQPO-MHARETSRSA-N P(1),P(4)-bis(5'-guanosyl) tetraphosphate Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=C(NC2=O)N)=C2N=C1 OLGWXCQXRSSQPO-MHARETSRSA-N 0.000 claims abstract description 13
- OLGWXCQXRSSQPO-UHFFFAOYSA-N diguanosine tetraphosphate Natural products C1=NC(C(N=C(N)N2)=O)=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OCC(C(O)C1O)OC1N1C=NC2=C1NC(N)=NC2=O OLGWXCQXRSSQPO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- -1 pyrrolidone sodium carboxylates Chemical class 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930182470 glycoside Natural products 0.000 claims abstract description 9
- 239000004006 olive oil Substances 0.000 claims abstract description 9
- 235000008390 olive oil Nutrition 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 229910052708 sodium Inorganic materials 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 18
- 241000219173 Carica Species 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 16
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 11
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 238000006703 hydration reaction Methods 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 1
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 206010040880 Skin irritation Diseases 0.000 abstract description 7
- 230000036556 skin irritation Effects 0.000 abstract description 7
- 231100000475 skin irritation Toxicity 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 5
- 240000006432 Carica papaya Species 0.000 abstract description 4
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 230000019612 pigmentation Effects 0.000 abstract description 3
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 206010020718 hyperplasia Diseases 0.000 description 8
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000283977 Oryctolagus Species 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010072170 Skin wound Diseases 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000037314 wound repair Effects 0.000 description 4
- 235000006264 Asimina triloba Nutrition 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 230000002390 hyperplastic effect Effects 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000009418 renovation Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- AFHJQYHRLPMKHU-OSYMLPPYSA-N aloin A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-OSYMLPPYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 1
- 210000002347 langhans' cell Anatomy 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000874 microwave-assisted extraction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical class CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种疤痕修复剂,该疤痕修复剂包括如下组分及其重量份数:燕麦多肽1~2份、木瓜提取物0.5~6份、蜗牛分泌液0.05~1份、L‑吡咯烷酮羧酸钠2~4份、四磷酸二鸟苷0.1~0.5份、细胞因子脂质体1~2份、乙基己基甘油3~6份、橄榄油10~20份、烷基糖苷2~4份和水30~50份。所述的疤痕修复剂各成分相互协调,疤痕修复效果显著,且无皮肤刺激性,安全性高,并兼具保湿嫩肤、抗氧化抗衰老的功效,可有效淡化疤痕色斑,抑制色素沉着,使皮肤恢复至自然状态,均匀肤色,同时可抚平细纹,促进皮肤紧致。
Description
技术领域
本发明涉及疤痕修复技术领域,具体涉及一种疤痕修复剂及其制备方法。
背景技术
疤痕是人体的皮肤组织受到外界各种创伤之后,在伤口愈合之处的皮肤纤维***增生充填、连接、支持、保护周围正常组织而形成。目前对于疤痕形成的机制尚未完全清楚,一般认为是创伤修复中成纤维细胞的大量增殖与凋亡抑制,细胞外基质中胶原的合成与降解失衡,相关的细胞因子的表达异常等构成了疤痕形成的生物学基础。
疤痕不仅破坏了体表美,还可能影响相关组织或器官的功能,更严重者还能导致畸形。随着生活质量的提高,人们对于影响皮肤美观的疤痕的修复越来越关注,继而有效的祛疤治疗方法成为了临床和美容界关注的热点。目前对疤痕的治疗多采用手术疗法、加压疗法、皮质类固醇注射疗法、放射疗法、冷冻激光疗法、硅凝胶疗法和生物疗法等。其中,随着生物技术的发展,人们意识到将生物活性成分应用于疤痕的治疗,疗效显著,且安全性高,如公开号为:CN 102552099 B中国专利申请“一种用于皮肤美容修复的复合生物制剂及制备方法”,将从脐带血干细胞中提取的干细胞活性成分,以及从胎盘中提取的胎盘活性成分,制成复合生物制剂,具有较佳的护肤祛疤祛斑的功效。又如公开号为CN 106110304 A的中国专利“一种祛疤组合物和敷料”,以间充质干细胞提取物、成纤维细胞生长因子和芦荟提取物作为有效成分,与Ⅰ型胶原蛋白、壳多糖、糖胺聚糖、海藻糖和戊二醇等支架成分混合,经3D打印和固化制成敷料,能够有效抑制疤痕处色素的沉积,消炎补水,滋养肌肤,促进细胞的新陈代谢,从而达到淡化疤痕,修复皮肤创面的功效。
虽然,近些年来针对祛疤研发的各类产品层出不穷,但疗效显著、安全性高、使用方便并可产业化生产的产品还是相对较少,不能满足市场的需要。
发明内容
为解决现有技术存在的问题,本发明的目的在于提供一种疤痕修复剂及其制备方法,该修复剂各成分相互协调,疤痕修复效果显著,且无皮肤刺激性,安全性高。
本发明的技术方案如下:
一种疤痕修复剂,其包括如下组分及其重量份数:燕麦多肽0.5~4份、蜗牛分泌液0.01~2份、L-吡咯烷酮羧酸钠1~6份、四磷酸二鸟苷0.05~1份、细胞因子脂质体1~4份、乙基己基甘油1~8份、橄榄油10~20份、烷基糖苷1~5份和水30~50份。
优选地,所述的疤痕修复剂包括如下组分及其重量份数:燕麦多肽1~2份、蜗牛分泌液0.05~1份、L-吡咯烷酮羧酸钠2~4份、四磷酸二鸟苷0.1~0.5份、细胞因子脂质体1~2份、乙基己基甘油3~6份、橄榄油10~20份、烷基糖苷2~4份和水30~50份。
进一步地,上述的疤痕修复剂还包含木瓜提取物0.5~6份。
优选地,所述的疤痕修复剂包括如下组分及其重量份数:燕麦多肽1~2份、木瓜提取物0.5~6份、蜗牛分泌液0.05~1份、L-吡咯烷酮羧酸钠2~4份、四磷酸二鸟苷0.1~0.5份、细胞因子脂质体1~2份、乙基己基甘油3~6份、橄榄油10~20份、烷基糖苷2~4份和水30~50份。
进一步地,所述的细胞因子脂质体,按重量份数计,包含以下组分:重组人白细胞介素-12 0.0001~0.002份、橙皮苷0.01~0.2份、氢化卵磷脂60~100份、胆固钠0.5~4份、胆固醇10~30份。
优选地,所述的细胞因子脂质体,按重量份数计,包含以下组分:重组人白细胞介素-120.0005~0.0010份、橙皮苷0.05~0.1份、氢化卵磷脂80~100份、胆固钠1~2份、胆固醇20~30份。
进一步地,所述的细胞因子脂质体的制备包括以下步骤:
(1)称取氢化卵磷脂、胆固钠和胆固醇,加入无水乙醇,制成浓度为2~5mg/mL的溶液A;
(2)取橙皮苷加入二甲基甲酰胺,制成浓度为0.1~0.2mg/mL的溶液B;
(3)取重组人白细胞介素-12加入pH为7.4的磷酸盐缓冲溶液,制成浓度为0.01~0.1mg/mL的溶液C;
(4)将溶液A和溶液B混合,在28℃,0.1MPa的条件下旋转蒸发,除去乙醇和二甲基甲酰胺,静置5~10min,加入溶液C,在35℃水浴中振荡水化反应约1h,得脂质体悬浮液,然后使用注射器式滤器调整脂质体悬浮液的粒径至100~150nm,即得。
此外,本发明还提供一种所述的疤痕修复剂的制备方法,其包括以下步骤:
(1)称取燕麦多肽、蜗牛分泌液、L-吡咯烷酮羧酸钠和四磷酸二鸟苷,溶于水,备用;
(2)称取乙基己基甘油和橄榄油,混合,依次加入步骤(1)得到的水溶液、烷基糖苷、细胞因子脂质体,搅拌乳化,即得。
进一步地,所述步骤(1)还包括称取木瓜提取物的步骤。
本发明疤痕修复剂中的木瓜提取物可以为市售产品,也可以通过提取方法自行制备,具体地,所述的木瓜提取物的制备包括以下步骤:
取木瓜饮片100kg,干燥后粉碎,加入药材总重量10~12倍量体积分数为60~80%的乙醇,微波提取8~15分钟,微波功率为400~600W,提取温度为40~60℃,过滤将滤液减压回收乙醇至无醇味,上D101大孔吸附树脂柱,用水充分洗脱至流出液为澄清且无还原糖反应后,再用60~80%乙醇洗脱,收集60~80%乙醇洗脱液,减压浓缩至无醇味,滤过,加入10%氢氧化钠溶液调pH值为9.0,加2倍量水饱和正丁醇萃取两次,合并正丁醇液,减压浓缩至近干,减压干燥,得木瓜提取物。
进一步地,本发明木瓜提取物中含有木瓜总皂苷的含量不低于40%(m/m)。
在本发明的疤痕修复剂中,通过燕麦多肽、木瓜提取物、蜗牛分泌液、L-吡咯烷酮羧酸钠、四磷酸二鸟苷和细胞因子脂质体的共同作用,可促进其对堆积的Ⅰ型胶原的降解,并显著减少纤维连接蛋白的表达,降低成纤维细胞密度,减缓瘢痕的生成,降低瘢痕增生指数,显示较佳的疤痕修复效果效果。同时所述的疤痕修复剂能够为皮肤基质细胞提供充足的营养,大大加快新皮肤组织的重构速度,从内而外修复皮肤,既杜绝感染、溃疡的可能,又使新生皮肤润泽光滑,祛疤美肤,实现皮肤的修复再生。
在本发明的疤痕修复剂中,所述的四磷酸二鸟苷(GP4G)是一种从海洋浮游生物中提取的能量物质,具有DNA保护和修复的功能,激活皮肤细胞的各种生理活动和新陈代谢。所述的蜗牛分泌液含软骨素硫酸盐天然元素,可代谢老化角质,促进纤维母细胞合成新生,具有淡化疤痕。所述的木瓜提取物通过下调转化生长因子-β1、***生长因子、纤维连接蛋白的表达,抑制瘢痕组织成纤维细胞增殖并诱导其凋亡,进而减缓瘢痕的生成。同时,所述燕麦多肽具有较佳的成膜性和保湿性,可使四磷酸二鸟苷、蜗牛分泌液、木瓜提取物等物质持久有效地深入渗进皮肤,锁住皮肤水分,赋予肌肤滋润,对皮肤粗糙具有较佳的修复效果,增加皮肤弹性和平滑性。所述的L-吡咯烷酮羧钠是皮肤角质层中的主要成分,具有较强的保湿性,可显著减轻皮肤的起皱现象,使疤痕修复剂充分地贴敷于皮肤的表面,发挥功效。
在本发明的疤痕修复剂中,所述的细胞因子脂质体含有重组人白细胞介素-12(rhIL-12)和橙皮苷,不仅可有效提高rhIL-12和橙皮苷的稳定性,同时以脂质体形式存在,可促进rhIL-12和橙皮苷深入渗透肌肤而发挥功效。其中,rhIL-12是由p40和p35两个亚单位通过多对二硫键组成的异二聚体蛋白,可透皮吸收至真皮和皮下组织,通过朗罕氏细胞介导可以活化真皮的T淋巴细胞,促使其产生γ-干扰素,而γ-干扰素可以抑制纤维母细胞增殖,抑制胶原合成所需要的脯氨酸羟化酶,阻止胶原产生,还能刺激胶原酶的分泌,促进胶原水解,降低纤维母细胞I、III型胶原的mRNA水平,抑制纤维母细胞分泌碱性纤维母细胞生长因子(bFGF),进而抑制胶原合成,阻止疤痕增生。橙皮苷具有具维生素P样效能,促进皮肤微血管循环,使rhIL-12能迅速发挥疗效,同时橙皮苷的抗氧化性可淡化色斑,消除疤痕形成过程中色素沉着,使肌肤恢复至自然状态。
与现有技术相比,本发明的优势在于:
(1)本发明提供的疤痕修复剂以燕麦多肽、木瓜提取物、蜗牛分泌液、L-吡咯烷酮羧酸钠、四磷酸二鸟苷和细胞因子脂质体为主要活性成分,相互协同,可有效抑制胶原的合成,减少纤维连接蛋白的表达,降低成纤维细胞密度,疤痕修复效果显著,作用温和,无皮肤刺激性,安全性高。
(2)本发明提供的疤痕修复剂兼具保湿嫩肤、抗氧化抗衰老的功效,可有效淡化疤痕色斑,抑制色素沉着,使皮肤恢复至自然状态,均匀肤色,同时可抚平细纹,促进皮肤紧致。
(3)本发明提供的疤痕修复剂质量稳定,仅含少量的rhIL-12,在降低成本的同时,获得较佳的疤痕修复效果,并制备方法简单,易于实施。
具体实施方式
以下通过具体实施方式进一步描述本发明,但本发明不仅仅限于以下实施例。
实施例1细胞因子脂质体的制备
A组脂质体制备:
(1)称取氢化卵磷脂、胆固钠和胆固醇,加入无水乙醇,制成浓度为4mg/mL的溶液A;
(2)取橙皮苷加入二甲基甲酰胺,制成浓度为0.2mg/mL的溶液B;
(3)取rhIL-12加入pH为7.4的磷酸盐缓冲溶液,制成浓度为0.05mg/mL的溶液C;
(4)将溶液A和溶液B混合,在28℃,0.1MPa的条件下旋转蒸发,除去乙醇和二甲基甲酰胺,静置10min,加入溶液C,在35℃水浴中振荡水化反应约1h,得脂质体悬浮液,然后使用注射器式滤器调整脂质体悬浮液的粒径至150nm,即得。
B-E组脂质体的制备参考上述A组。
实施例2-4和对比例1-5疤痕修复剂的制备
本发明实施例2-4和对比例1-5疤痕修复剂的组成见下表所示,其中细胞因子脂质体由实施例1制得。
实施例2疤痕修复剂的制备:
(1)取燕麦多肽、木瓜提取物、蜗牛分泌液、L-吡咯烷酮羧酸钠、四磷酸二鸟苷溶于水,备用;
(2)取乙基己基甘油、橄榄油混合,依次加入步骤(1)得到的水溶液、烷基糖苷、实施例1B组制得的细胞因子脂质体,搅拌乳化,即得。
实施例3、4和对比例1-5疤痕修复剂的制备,参考上述的方法。
试验例一、皮肤刺激性试验
1、试验方法:选取80只新西兰兔,雌雄各半,体重为2.5kg,随机分为实施例2、3、4组和对比例1-5组,每组10只,雌雄各半,各组分别对应涂抹各实施例和对比例制得的疤痕修复剂。试验前24h,将新西兰兔背部脊柱侧脱毛,去毛范围右侧3cm×3cm。在给受试样品前仔细检查去毛皮肤是否因去毛而受损伤,有损伤的皮肤不宜进行试验。将受试新西兰兔固定于兔固定盒中,用0.5g试验材料涂抹于右侧已去毛的皮肤上,涂抹面积为(2.5×2.5)cm2,每天涂抹一次,连续涂抹14d。从第2天开始,每次涂抹前应剪毛,用温水清除残留受试样品,1h后观察结果。进行皮肤刺激反应评分。涂抹时间为23h,涂抹后,将受试新西兰兔放回兔饲养笼饲养。观察涂抹部位有无红斑、水肿形成,并按表1所示皮肤刺激反应评分标准进行评分,皮肤刺激强度分级如表2所示。
表1皮肤刺激反应评分标准
表2皮肤刺激强度分级
皮肤刺激指数 | 刺激强度级别 |
0~0.49 | 无刺激性 |
0.5~1.99 | 轻度刺激性 |
2.0~5.99 | 中度刺激性 |
6.0~8.0 | 重度刺激性 |
2、试验结果
表3各组疤痕修复剂对新西兰兔多次皮肤刺激性评价结果
以上结果表明,本发明实施例2-4和对比例1-5制得的疤痕修复剂,性质温和,无皮肤刺激性,安全性高。
试验例二、人体皮肤斑贴试验
参照***发布的2015版《化妆品卫生规范》中“人体皮肤斑贴试验”的相关要求和测定方法对本发明实施例2-4、对比例1-5的疤痕修复剂进行测试,分别在0h、6h、12h、24h、48h观察皮肤反应,所有志愿受试者的实验结果均为阴性结果,未出现皮肤不良反应。表明本发明提供的疤痕修复剂无刺激性,安全性高。
试验例三、疤痕修复剂对兔子皮肤病理性瘢痕的影响
采用3%戊巴比妥钠1.5mg/kg兔耳耳缘静脉麻醉,角膜反射迟钝即麻醉成功,沿兔子耳腹面侧长轴制作直径为1cm╳0.5cm大小的梭形创面,每耳6处,间隔至少2cm,完整切除全层皮肤,去除软骨膜,保留软骨,创面不予任何处理,任其自然愈合,4周后兔耳创面基本愈合,增生块达到高峰,创面约为耳廓厚度的3倍,造模成功。将造模成功的兔子随机分为9组,分别为空白组、实施例2-4组、对比例1-5组,每组6只。其中,空白组不作任何处理,实施例2-4组、对比例1-5组分别涂抹本发明实施例2-4组、对比例1-5组制得的祛疤组合物,每天涂抹3次,连续观察1个月,取材,经固定、脱水、包埋、切片、HE染色等步骤制片,在光镜下观察瘢痕增生指数和成纤维细胞数密度,并采用免疫组化方法检测纤维连接蛋白(FN)的表达。
其中,测定瘢痕增生指数:HE染色切片,低倍镜下用纤维测量尺测量,并计算瘢痕增生指数。计算公式为:瘢痕增生指数=瘢痕突起最高点至耳软骨表面的垂直高度/瘢痕周围正常皮肤表面至耳软骨表面的垂直高度。
成纤维细胞数密度:HE染色切片,400倍光镜下观察在瘢痕中央浅部、中央深部、两侧部各随机选取10个矩形视野,目测计数并计算切片内单位面积成纤维细胞的数量,结果取均数。
表4各试验组对兔耳病理性瘢痕的增生指数、成纤维细胞密度和FN表达的影响
注:与同组治疗前比较,*P<0.05,**P<0.01;与空白组比较,#P<0.05,##P<0.01.
由上表可知,与治疗前比较,本发明实施例2-4制得的疤痕修复剂可显著降低兔耳病理性瘢痕组织的瘢痕增生指数和成纤维细胞密度,并可显著减少纤维连接蛋白的表达减轻瘢痕增生,促进瘢痕的消除。由对比例1和2可知,不含木瓜提取物、细胞因子脂质体的疤痕修复剂对瘢痕增生指数的抑制作用以及降低成纤维细胞密度、减少纤维连接蛋白表达的效果不显著,表明木瓜提取物和细胞因子脂质体对疤痕修复发挥着重要的作用。由对比例3-5可知,仅含rhIL-12的脂质体,或含γ-干扰素和橙皮苷的脂质体,或含芦荟苷和rhIL-12的脂质体制得的疤痕修复剂对瘢痕增生指数的抑制作用以及降低成纤维细胞密度、减少纤维连接蛋白表达的效果呈现出不同程度的减弱,表明细胞因子脂质体中rhIL-12和橙皮苷两者相互协调,促进疤痕修复。
试验例四、疤痕修复剂的临床疗效评价
选取广州某医院2015年1月~2015年12月收治的深II度及以上严重烧烫伤导致的增生性疤痕患者志愿者120人(男72人,女48人,年龄20~45岁,平均年龄32.7岁)进行增生性疤痕的修复试验,烧烫伤病程0.5~4个月,均已形成增生性疤痕,疤痕厚度在2.02~2.40mm之间,疤痕组织色泽红润,质地坚硬。随机分为6组,每组20人,分别为实施例3组、对比例1-5组,各组分别涂抹本发明实施例3组、对比例1-5组制得的疤痕修复剂,每日涂抹3次,连续涂抹2个月,评价疗效,其中,效评价标准为:治愈:痛、痒、灼感消失,疤痕组织色泽变暗,质地***,表面光滑,外观感觉良好;显效:痛、痒、灼感基本消失,疤痕大部分***,外观感觉较好;有效:痛、痒、灼感明显减轻,疤痕一定程度萎缩,疤痕高度降低;无效:痛、痒、灼感无明显减轻或加重,疤痕色泽、大小、高度无明显改变。
表5本发明提供的疤痕修复剂的临床治疗效果
由上表可知,本发明实施例3制得的疤痕修复剂对增生性疤痕的治疗效果显著,连续使用2个月后,治愈例数为10例,疤痕厚度降至0.36mm,总有效率达100%,显著优于对比例1-5组。
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.一种疤痕修复剂,其特征在于,所述的疤痕修复剂包括如下组分及其重量份数:燕麦多肽0.5~4份、木瓜提取物0.5~6份、蜗牛分泌液0.01~2份、L-吡咯烷酮羧酸钠1~6份、四磷酸二鸟苷0.05~1份、细胞因子脂质体1~4份、乙基己基甘油1~8份、橄榄油10~20份、烷基糖苷1~5份和水30~50份;
其中,所述的细胞因子脂质体,按重量份数计,包含以下组分:重组人白细胞介素-120.001份、橙皮苷0.1份、氢化卵磷脂90份、胆固钠2份、胆固醇25份。
2.根据权利要求1所述的疤痕修复剂,其特征在于,所述的疤痕修复剂包括如下组分及其重量份数:燕麦多肽1~2份、木瓜提取物0.5~6份、蜗牛分泌液0.05~1份、L-吡咯烷酮羧酸钠2~4份、四磷酸二鸟苷0.1~0.5份、细胞因子脂质体1~2份、乙基己基甘油3~6份、橄榄油10~20份、烷基糖苷2~4份和水30~50份。
3.根据权利要求1所述的疤痕修复剂,其特征在于,所述的细胞因子脂质体的制备包括以下步骤:
(1)称取氢化卵磷脂、胆固钠和胆固醇,加入无水乙醇,制成浓度为2~5 mg/mL的溶液A;
(2)取橙皮苷加入二甲基甲酰胺,制成浓度为0.1~0.2 mg/mL的溶液B;
(3)取重组人白细胞介素-12加入pH为7.4的磷酸盐缓冲溶液,制成浓度为0.01~0.1mg/mL的溶液C;
(4)将溶液A和溶液B混合,在28℃,0.1MPa的条件下旋转蒸发,除去乙醇和二甲基甲酰胺,静置5~10min,加入溶液C,在35℃水浴中振荡水化反应1h,得脂质体悬浮液,然后使用注射器式滤器调整脂质体悬浮液的粒径至100~150nm,即得。
4.根据权利要求1所述的疤痕修复剂的制备方法,其特征在于,包括以下步骤:
(1)称取燕麦多肽、蜗牛分泌液、L-吡咯烷酮羧酸钠和四磷酸二鸟苷,溶于水,备用;
(2)称取乙基己基甘油和橄榄油,混合,依次加入步骤(1)得到的水溶液、烷基糖苷、细胞因子脂质体,搅拌乳化,即得。
5.根据权利要求4所述的疤痕修复剂的制备方法,其特征在于,所述的细胞因子脂质体的制备包括以下步骤:
(1)称取氢化卵磷脂、胆固钠和胆固醇,加入无水乙醇,制成浓度为2~5 mg/mL的溶液A;
(2)取橙皮苷加入二甲基甲酰胺,制成浓度为0.1~0.2 mg/mL的溶液B;
(3)取重组人白细胞介素-12加入pH为7.4的磷酸盐缓冲溶液,制成浓度为0.01~0.1mg/mL的溶液C;
(4)将溶液A和溶液B混合,在28℃,0.1MPa的条件下旋转蒸发,除去乙醇和二甲基甲酰胺,静置5~10min,加入溶液C,在35℃水浴中振荡水化反应1h,得脂质体悬浮液,然后使用注射器式滤器调整脂质体悬浮液的粒径至100~150nm,即得。
6.根据权利要求4所述的疤痕修复剂的制备方法,其特征在于,所述步骤(1)还包括称取木瓜提取物的步骤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710631595.4A CN107375906B (zh) | 2017-07-28 | 2017-07-28 | 一种疤痕修复剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710631595.4A CN107375906B (zh) | 2017-07-28 | 2017-07-28 | 一种疤痕修复剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107375906A CN107375906A (zh) | 2017-11-24 |
CN107375906B true CN107375906B (zh) | 2018-06-08 |
Family
ID=60342472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710631595.4A Active CN107375906B (zh) | 2017-07-28 | 2017-07-28 | 一种疤痕修复剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107375906B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108635312A (zh) * | 2018-04-10 | 2018-10-12 | 荣延洲 | 一种植物精华疤痕修复液及其制备方法 |
CN108969508A (zh) * | 2018-09-21 | 2018-12-11 | 珠海汉盈科技有限公司 | 含有芦荟提取物的促进烧伤创面修复的自发热膜 |
CN109010195A (zh) * | 2018-10-13 | 2018-12-18 | 陈洁珍 | 一种美白除皱祛疤修复护肤霜及其制备方法 |
CN110251412A (zh) * | 2019-06-27 | 2019-09-20 | 广东暨大基因药物工程研究中心有限公司 | 重组人白细胞介素-12脂质体的制备方法及其产品用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102038937A (zh) * | 2009-10-12 | 2011-05-04 | 张志群 | 治疗皮肤病及防衰老的外用药及其制备方法 |
CN102965418A (zh) * | 2012-12-12 | 2013-03-13 | 上海相宜本草化妆品股份有限公司 | 生物燕麦多肽的提取方法及其用途 |
CN104974207A (zh) * | 2014-04-03 | 2015-10-14 | 珀莱雅化妆品股份有限公司 | 一种从咸水卤虫卵中提取四磷酸二鸟苷的方法 |
CN105902461A (zh) * | 2016-05-11 | 2016-08-31 | 广州智媛生物科技有限公司 | 一种含蜗牛粘液提取物的精华液及其制备方法 |
CN106860166A (zh) * | 2017-02-24 | 2017-06-20 | 长沙协浩吉生物工程有限公司 | 一种酵素祛痘爽肤水的配制方法 |
-
2017
- 2017-07-28 CN CN201710631595.4A patent/CN107375906B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102038937A (zh) * | 2009-10-12 | 2011-05-04 | 张志群 | 治疗皮肤病及防衰老的外用药及其制备方法 |
CN102965418A (zh) * | 2012-12-12 | 2013-03-13 | 上海相宜本草化妆品股份有限公司 | 生物燕麦多肽的提取方法及其用途 |
CN104974207A (zh) * | 2014-04-03 | 2015-10-14 | 珀莱雅化妆品股份有限公司 | 一种从咸水卤虫卵中提取四磷酸二鸟苷的方法 |
CN105902461A (zh) * | 2016-05-11 | 2016-08-31 | 广州智媛生物科技有限公司 | 一种含蜗牛粘液提取物的精华液及其制备方法 |
CN106860166A (zh) * | 2017-02-24 | 2017-06-20 | 长沙协浩吉生物工程有限公司 | 一种酵素祛痘爽肤水的配制方法 |
Non-Patent Citations (1)
Title |
---|
瘢痕的形成机制及天然产物对其治疗的研究进展;李子安等;《中国美容医学》;20160731;第25卷(第7期);第105-109页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107375906A (zh) | 2017-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107375906B (zh) | 一种疤痕修复剂及其制备方法 | |
CN102762189B (zh) | 包含长角豆提取物作为促进水通道蛋白表达活性剂的化妆品和/或药物组合物 | |
CN107854418A (zh) | 一种人脐带间充质干细胞外泌体外用乳霜及其制备方法 | |
CN104644461A (zh) | 具有促进胶原蛋白合成活性的化合物在抗衰老化妆品中的应用 | |
TWI625134B (zh) | 間質幹細胞萃取物及其用途 | |
KR101912329B1 (ko) | 세포 외 기질을 모사한 피부 세포 재생용 화장료 조성물 | |
CN112321723B (zh) | 一种抗皮肤光老化多肽类化合物及其应用 | |
CN101791283A (zh) | 一种可消除妊娠纹和疤痕的化妆品 | |
KR101098400B1 (ko) | 홍삼 먹인 달팽이 점액의 제조방법 및 이를 함유하는 화장료 조성물 | |
CN114601748A (zh) | 一种舒缓修复组合物及其应用 | |
CN108618986A (zh) | 一种保湿祛皱多功能面膜液及其制备方法 | |
KR20200078433A (ko) | 다양한 성장인자와 펩타이드를 함유하는 주름개선 및 미백용 화장료 조성물 | |
CN109010195A (zh) | 一种美白除皱祛疤修复护肤霜及其制备方法 | |
US9675628B2 (en) | Method for producing a mixture of neutral oligosaccharides extracted from flaxseed | |
KR102452905B1 (ko) | 천연 스피큘과 폴리디옥사논을 함유한 피부개선 화장조성물 제조방법 및 그 화장조성물 | |
KR101895037B1 (ko) | 스피큘을 포함하는 하이드로겔 조성물 및 이의 용도 | |
KR102026409B1 (ko) | 유근피 또는 유백피 파우더를 유효성분으로 포함하는 창상 치료 및 피부 재생용 조성물 | |
CN117106712B (zh) | 一种用于皮肤再生的干细胞外泌体及其应用和产品 | |
Chen et al. | Wound healing effects of cactus extracts on second degree superficial burned mice | |
CN1823724A (zh) | 大鲵美容护肤品及其制备方法 | |
Garcia, X. Santos Heredero, Á. Izquierdo Hernandez, E. Pascual Peña, G. Bilbao Gonzalez de Aledo, C. Hamann | Experimental model for local application of growth factors in skin re-epithelialisation | |
CN107174536A (zh) | 一种大鲵美容护肤品及其制备方法 | |
CN113520899B (zh) | 一种用于皮肤光损伤修复的重组胶原蛋白产品 | |
KR102052107B1 (ko) | 화장료 조성물 | |
KR20120140450A (ko) | 인간 중간엽줄기세포의 분화 촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230705 Address after: Room 101, No. 39 Baoying Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510700, self-made unit 102 Patentee after: Guangdong Huasang Lixi Biotechnology Co.,Ltd. Address before: Room 301, 401, 39 BAOYING Avenue, Guangzhou Free Trade Zone, Guangdong 510730 Patentee before: GUANGDONG COOWAY BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |